Multiple Sclerosis Pill (Laquinimod ) Reduced Brain Lesions in Trial
Posted Jan 14 2009 8:24pm
Teva's Multiple Sclerosis Pill Reduced Brain Lesions in Trial
By Alex Kuli
June 20 (Bloomberg) -- Teva Pharmaceutical Industries Ltd.'sexperimental multiple sclerosis pill helped reduce brain lesions in a new study, moving the Israeli drugmaker closer to introducing the first oral treatment for the disabling disease.
Patients with the relapsing-remitting form of the illness on a daily dose of the medicine, laquinimod, had 40 percent fewer brain lesions than those on a placebo, according to the study in The Lancet medical journal. Lesions are caused when the immune system attacks the fatty tissue around nerve fibers, breaking the connection between brain and muscle.
By Alex Kuli
June 20 (Bloomberg) -- Teva Pharmaceutical Industries Ltd.'sexperimental multiple sclerosis pill helped reduce brain lesions in a new study, moving the Israeli drugmaker closer to introducing the first oral treatment for the disabling disease.
Patients with the relapsing-remitting form of the illness on a daily dose of the medicine, laquinimod, had 40 percent fewer brain lesions than those on a placebo, according to the study in The Lancet medical journal. Lesions are caused when the immune system attacks the fatty tissue around nerve fibers, breaking the connection between brain and muscle.
» Read More
.